Hims enters a “strategic pivot” following blowback from its copycat Wegovy pill

After selling compounded GLP-1 drugs for two years, Hims is launching an expensive shift to branded treatments.

J. Edward Moreno
Author: J. Edward Moreno

Source: Sherwood News.

Written by

J. Edward Moreno

in

More posts